FDA Issues Warning on Controversial MS Treatment
Doctors and patients need to be aware of the potential risk of injuries and death associated with an experimental treatment for multiple sclerosis called liberation therapy, the U.S. Food and Drug Administration said in an alert issued Thursday. Liberation therapy is used to treat chronic cerebrospinal venous insufficiency (CCSVI) – a narrowing of veins in the neck and chest – believed by some to cause multiple sclerosis (MS) or worsen the disease. "The FDA's action is well-founded and provides an important safeguard for individuals with MS," he said. He also said the very existence of chronic cerebrospinal venous insufficiency is unclear. And, "whether there is any relationship between CCSVI and MS, as either a cause or consequence, is unproven," he added.
- Dr. Fred Lublin, Professor, Neurology, Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, The Mount Sinai Medical Center
Learn more: http://www.philly.com/philly/health/HealthDay664650_20120510_FDA_Issues_Warning_on_Controversial_MS_Treatment.html?cmpid=138896554
Mount Sinai Launches Institute for Regenerative Medicine
Apr 24, 2023 View All Press Releases
